Immune checkpoint inhibitors targeting PD‐1/PD‐L1 have displayed favorable efficacy in clinical settings.[66] However, the effectiveness of immunotherapy for HCC is limited, with a response rate of <30%, which could be attributed to immune microenvironment tolerance, inadequate tumor antigen exposure, and insufficient infiltration of T cells in HCC.[67, 68] Therefore, immunotherapy is commonly used as an adjunctive therapy, along with other traditional therapies, to improve the overall treatment outcomes, potentially hindering tumor reappearance and dissemination. This evidence concerns the gene PDCD1 and neoplasm.